Effectiveness and Safety of the MVA–BN Vaccine against Mpox in At-Risk Individuals in the United States (USMVAc)

Abstract

The mpox 2022 outbreak was declared a public health emergency in July 2022. In August 2022, the MVA–BN vaccine received emergency use authorization in the United States (US) to target at-risk groups. This study (EUPAS104386) used HealthVerity’s administrative US healthcare data to generate real-world evidence for MVA–BN vaccine effectiveness and safety to prevent mpox disease in men who have sex with men (MSM) and transgender women, the most affected population during the 2022 mpox outbreak. Fully vaccinated subjects (two doses ≥ 28 days apart) were initially matched with five unvaccinated subjects on calendar date, age, US region, and insurance type. Subjects were followed from index date (14 days after the second dose) until death or data end to ascertain mpox occurrence. After propensity score adjustment, the MVA–BN vaccine effectiveness against mpox disease was 89% (95% CI: 12%, 99%) among those fully vaccinated; attenuated to 64% (95% CI: 40%, 78%) among those with any dose and 70% (95% CI: 44%, 84%) for those with only a single dose. One pericarditis adverse event of special interest was observed when the risk window was extended to 28 days. These results contribute to the totality of evidence supporting the favorable benefit/risk profile of the MVA–BN vaccine.

Keywords

• vaccine effectiveness
• vaccine safety
• MVA–BN
• mpox (monkeypox)
• real-world evidence (RWE)